NO794295L - Fremgangsmaate til fremstilling av et antibakterielt preparat med forlenget virkningsvarighet - Google Patents
Fremgangsmaate til fremstilling av et antibakterielt preparat med forlenget virkningsvarighetInfo
- Publication number
- NO794295L NO794295L NO794295A NO794295A NO794295L NO 794295 L NO794295 L NO 794295L NO 794295 A NO794295 A NO 794295A NO 794295 A NO794295 A NO 794295A NO 794295 L NO794295 L NO 794295L
- Authority
- NO
- Norway
- Prior art keywords
- penicillanic acid
- methyleneamino
- hexahydro
- pharmaceutically acceptable
- compounds
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims description 20
- 230000000844 anti-bacterial effect Effects 0.000 title claims description 12
- 238000000034 method Methods 0.000 title claims description 8
- RBKMMJSQKNKNEV-RITPCOANSA-N penicillanic acid Chemical compound OC(=O)[C@H]1C(C)(C)S[C@@H]2CC(=O)N21 RBKMMJSQKNKNEV-RITPCOANSA-N 0.000 claims description 27
- 150000001875 compounds Chemical class 0.000 claims description 18
- 229930182555 Penicillin Natural products 0.000 claims description 12
- BWWVAEOLVKTZFQ-NTZNESFSSA-N Amdinocillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)=CN1CCCCCC1 BWWVAEOLVKTZFQ-NTZNESFSSA-N 0.000 claims description 11
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- 150000002148 esters Chemical class 0.000 claims description 8
- 229940049954 penicillin Drugs 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 229960003669 carbenicillin Drugs 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 235000019371 penicillin G benzathine Nutrition 0.000 claims description 2
- 229940056360 penicillin g Drugs 0.000 claims description 2
- 230000000694 effects Effects 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 11
- 238000000338 in vitro Methods 0.000 description 10
- 241000894006 Bacteria Species 0.000 description 7
- 150000002960 penicillins Chemical class 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 238000013207 serial dilution Methods 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- -1 acetoxymethyl Chemical group 0.000 description 4
- 229950008796 bacmecillinam Drugs 0.000 description 4
- XHKFBADIZIDYBU-MLFVOLAISA-N chembl2106658 Chemical compound N(/[C@H]1[C@@H]2N(C1=O)[C@H](C(S2)(C)C)C(=O)OC(C)OC(=O)OCC)=C\N1CCCCCC1 XHKFBADIZIDYBU-MLFVOLAISA-N 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 229940024554 amdinocillin Drugs 0.000 description 3
- 229960002699 bacampicillin Drugs 0.000 description 3
- PFOLLRNADZZWEX-FFGRCDKISA-N bacampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)[C@H](C(S3)(C)C)C(=O)OC(C)OC(=O)OCC)=CC=CC=C1 PFOLLRNADZZWEX-FFGRCDKISA-N 0.000 description 3
- BWWVAEOLVKTZFQ-ISVUSNJMSA-N chembl530 Chemical compound N(/[C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)=C\N1CCCCCC1 BWWVAEOLVKTZFQ-ISVUSNJMSA-N 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 208000035143 Bacterial infection Diseases 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 241000305071 Enterobacterales Species 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000013421 nuclear magnetic resonance imaging Methods 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 238000012754 cardiac puncture Methods 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB5067571A GB1405886A (en) | 1971-11-01 | 1971-11-01 | Synergistic compositions comprising penicillin and cephalosporin antibiotics |
Publications (1)
Publication Number | Publication Date |
---|---|
NO794295L true NO794295L (no) | 1973-05-03 |
Family
ID=10456894
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO794295A NO794295L (no) | 1971-11-01 | 1979-12-27 | Fremgangsmaate til fremstilling av et antibakterielt preparat med forlenget virkningsvarighet |
Country Status (10)
Country | Link |
---|---|
US (1) | US4956179A (sv) |
JP (1) | JPS4852917A (sv) |
AT (1) | AT324550B (sv) |
AU (1) | AU474065B2 (sv) |
DE (2) | DE2265533C2 (sv) |
FR (1) | FR2158427B1 (sv) |
GB (1) | GB1405886A (sv) |
NL (1) | NL176525C (sv) |
NO (1) | NO794295L (sv) |
SE (1) | SE401087B (sv) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2508443C2 (de) * | 1974-02-28 | 1984-11-15 | Fujisawa Pharmaceutical Co., Ltd., Osaka | Pharmazeutisches Mischpräparat mit antibiotischer Wirkung |
GB1579931A (en) * | 1976-04-15 | 1980-11-26 | Leo Pharm Prod Ltd | Bis-penicillanoyl-oxy-alkanes |
US4345071A (en) | 1976-06-29 | 1982-08-17 | Leo Pharmaceutical Products, Ltd. A/S | Derivatives of penicillanic acid |
LU77362A1 (sv) * | 1977-05-17 | 1979-01-19 | ||
JPS542337A (en) * | 1977-06-08 | 1979-01-09 | Toyama Chem Co Ltd | Bactericidal composition for medical use |
IL54859A (en) * | 1977-06-21 | 1982-01-31 | Rech Applications Therap | Derivatives of amidinopenicillanic acid,their production and pharmaceutical compositions containing them |
JPS54126735A (en) * | 1978-03-24 | 1979-10-02 | Toyama Chem Co Ltd | Bactericidal composition for medical use |
NZ194785A (en) * | 1979-09-21 | 1983-05-31 | Leo Pharm Prod Ltd | Double-layer tablet containing penicillanic acid pro-drug in each layer |
US8366787B2 (en) * | 2000-08-04 | 2013-02-05 | Depuy Products, Inc. | Hybrid biologic-synthetic bioabsorbable scaffolds |
US6638312B2 (en) * | 2000-08-04 | 2003-10-28 | Depuy Orthopaedics, Inc. | Reinforced small intestinal submucosa (SIS) |
US7819918B2 (en) * | 2001-07-16 | 2010-10-26 | Depuy Products, Inc. | Implantable tissue repair device |
WO2003007847A1 (en) | 2001-07-16 | 2003-01-30 | Depuy Products, Inc. | Hybrid biologic-synthetic bioabsorable scaffolds |
WO2003007786A2 (en) | 2001-07-16 | 2003-01-30 | Depuy Products, Inc. | Porous delivery scaffold and method |
AU2002316696B2 (en) * | 2001-07-16 | 2007-08-30 | Depuy Products, Inc. | Cartilage repair and regeneration scaffold and method |
US7914808B2 (en) | 2001-07-16 | 2011-03-29 | Depuy Products, Inc. | Hybrid biologic/synthetic porous extracellular matrix scaffolds |
US8025896B2 (en) | 2001-07-16 | 2011-09-27 | Depuy Products, Inc. | Porous extracellular matrix scaffold and method |
WO2003007784A2 (en) | 2001-07-16 | 2003-01-30 | Depuy Products, Inc. | Meniscus regeneration device and method |
JP4197158B2 (ja) | 2001-07-16 | 2008-12-17 | デピュイ・プロダクツ・インコーポレイテッド | 天然に発生する生物学的に誘導されている材料による装置 |
US7163563B2 (en) | 2001-07-16 | 2007-01-16 | Depuy Products, Inc. | Unitary surgical device and method |
US7569233B2 (en) | 2004-05-04 | 2009-08-04 | Depuy Products, Inc. | Hybrid biologic-synthetic bioabsorbable scaffolds |
US7513866B2 (en) | 2004-10-29 | 2009-04-07 | Depuy Products, Inc. | Intestine processing device and associated method |
US7354627B2 (en) | 2004-12-22 | 2008-04-08 | Depuy Products, Inc. | Method for organizing the assembly of collagen fibers and compositions formed therefrom |
US7595062B2 (en) | 2005-07-28 | 2009-09-29 | Depuy Products, Inc. | Joint resurfacing orthopaedic implant and associated method |
US20070112360A1 (en) * | 2005-11-15 | 2007-05-17 | Patrick De Deyne | Bioprosthetic device |
US7871440B2 (en) | 2006-12-11 | 2011-01-18 | Depuy Products, Inc. | Unitary surgical device and method |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR1167424A (fr) * | 1952-10-29 | 1958-11-25 | American Home Prod | Procédé de fabrication de compositions de pénicilline |
GB1272660A (en) * | 1969-12-24 | 1972-05-03 | Beecham Group Ltd | Therapeutic compositions |
US4221781A (en) * | 1971-11-01 | 1980-09-09 | Astra Lakemedel Aktiebolag | Synergistic penicillin-cephalosporin compositions and methods |
-
1971
- 1971-11-01 GB GB5067571A patent/GB1405886A/en not_active Expired
-
1972
- 1972-10-18 DE DE2265533A patent/DE2265533C2/de not_active Expired
- 1972-10-18 DE DE2250993A patent/DE2250993C2/de not_active Expired
- 1972-10-25 AT AT910172A patent/AT324550B/de not_active IP Right Cessation
- 1972-10-25 AU AU48126/72A patent/AU474065B2/en not_active Expired
- 1972-10-26 NL NLAANVRAGE7214478,A patent/NL176525C/xx not_active IP Right Cessation
- 1972-10-31 SE SE7214083A patent/SE401087B/sv unknown
- 1972-10-31 FR FR7238691A patent/FR2158427B1/fr not_active Expired
- 1972-11-01 JP JP47108956A patent/JPS4852917A/ja active Pending
-
1979
- 1979-12-27 NO NO794295A patent/NO794295L/no unknown
-
1987
- 1987-07-02 US US07/069,787 patent/US4956179A/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
FR2158427B1 (sv) | 1976-07-02 |
NL176525B (nl) | 1984-12-03 |
GB1405886A (en) | 1975-09-10 |
FR2158427A1 (sv) | 1973-06-15 |
DE2250993A1 (de) | 1973-05-10 |
DE2250993C2 (de) | 1982-12-30 |
AU4812672A (en) | 1974-04-26 |
AU474065B2 (en) | 1976-07-15 |
JPS4852917A (sv) | 1973-07-25 |
DE2265533C2 (de) | 1983-12-29 |
NL176525C (nl) | 1985-05-01 |
NL7214478A (sv) | 1973-05-03 |
SE401087B (sv) | 1978-04-24 |
US4956179A (en) | 1990-09-11 |
AT324550B (de) | 1975-09-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO794295L (no) | Fremgangsmaate til fremstilling av et antibakterielt preparat med forlenget virkningsvarighet | |
KR0149672B1 (ko) | 클로스트리듐 디피실레 하리증 및 위막성 대장염의 예방 및 치료용 의약조성물 | |
Onderdonk et al. | Activity of metronidazole against escherichia coli in experimental infra-abdominal sepsis | |
CN1895666A (zh) | 奶牛乳房炎多联灭活菌苗 | |
CN109999027B (zh) | 褪黑素的用途 | |
JP2961182B2 (ja) | クロストリジウム・ディフィシル下痢症および偽膜性大腸炎の予防ならびに治療用医薬組成物 | |
CN110305193B (zh) | 一种抗牙龈卟啉单胞菌多肽及应用 | |
CN101003539A (zh) | 西林类化合物的氨丁三醇盐及其制备方法 | |
Waisbren et al. | Comparative action of aureomycin, chloromycetin, neomycin, Q-19, and polymyxin B against gram negative bacilli | |
CN101336903B (zh) | 注射用左旋奥硝唑磷酸二钠静脉制剂的制备方法 | |
CN108434438B (zh) | 抗菌肽在制备治疗幽门螺杆菌病的药物中的用途以及药物组合物 | |
CN113730401B (zh) | 水鬼蕉新碱a在制备抗菌的药物中的用途 | |
WO2019178954A1 (zh) | 琥珀酸在提高细菌对抗生素敏感性方面的应用 | |
CN113384586B (zh) | 原花青素黄酮类中药单体在协同增效头孢噻呋钠抗mrsa耐药菌作用的用途 | |
US20020114794A1 (en) | Staphylococcus aureus culture and preparation thereof | |
Florey et al. | The work on penicillin at Oxford | |
CN114009439B (zh) | 一类含氮离子化合物在抗植物病原细菌和人源病菌中的用途 | |
US10159708B2 (en) | Method for the treatment of acne | |
Rachma et al. | Secondary metabolite of Aspergillus oryzae impairs cell envelope integrity Klebsiella pneumoniae producing extended-spectrum beta-lactamase | |
Nutini et al. | Comparative Action of an Extract of Brain Tissue and Penicillin on Staphylococcus aureus Infections | |
CN110317247B (zh) | 一种抗口腔致病菌多肽及应用 | |
CN114097807B (zh) | 巴多索隆类化合物在抗农业病原真菌中的用途 | |
CN102462686A (zh) | 一种用于防治畜禽大肠杆菌病的药物组合物 | |
Davis et al. | URINARY ANTISEPSIS THE SECRETION OF ANTI-SEPTIC URINE FOLLOWING THE INTRAVENOUS ADMINISTRATION OF ACRIFLAVINE AND PRO-FLAVINE-PRELIMINARY REPORT | |
CN115569142B (zh) | 麦角甾醇在制备抗弧菌感染性疾病的药物中的应用 |